Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors

Jean Boucher, Linnea Olson, Bilal Piperdi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Epidermal growth factor receptor inhibitors (EGFRIs) are a treatment option for patients diagnosed with advanced-stage gastrointestinal, lung, and head and neck cancers. The most prevalent complications associated with EGFRIs are dermatologic toxicities, which may result in either disruption or discontinuation of treatment and adversely affect patients' quality of life. Nurses play a vital role in educating patients about EGFRI-related dermatologic toxicities; therefore, nurses must continue to educate themselves on the various aspects of EGFRI treatment. An overview of the EGF signaling pathway is provided, and dermatologic toxicities associated with EGFRI treatment are described. A review of several studies evaluating reactive skin treatment regimens also are discussed. Nurses play a critical role in providing patient support. Informing patients about potential EGFRI-related symptoms and dermatologic toxicities will help prepare patients for their course of treatment. In addition, nurses should provide patients with a variety of coping strategies to help manage dermatologic toxicities that will assist in enhancing patients' adherence to EGFRI treatment.

Original languageEnglish (US)
Pages (from-to)501-508
Number of pages8
JournalClinical Journal of Oncology Nursing
Volume15
Issue number5
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Nurses
Therapeutics
Patient Compliance
Head and Neck Neoplasms
Epidermal Growth Factor
Lung Neoplasms
Quality of Life
Skin

ASJC Scopus subject areas

  • Oncology(nursing)
  • Oncology

Cite this

Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors. / Boucher, Jean; Olson, Linnea; Piperdi, Bilal.

In: Clinical Journal of Oncology Nursing, Vol. 15, No. 5, 10.2011, p. 501-508.

Research output: Contribution to journalArticle

@article{42ecbe254590460eba9f401f2e798636,
title = "Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors",
abstract = "Epidermal growth factor receptor inhibitors (EGFRIs) are a treatment option for patients diagnosed with advanced-stage gastrointestinal, lung, and head and neck cancers. The most prevalent complications associated with EGFRIs are dermatologic toxicities, which may result in either disruption or discontinuation of treatment and adversely affect patients' quality of life. Nurses play a vital role in educating patients about EGFRI-related dermatologic toxicities; therefore, nurses must continue to educate themselves on the various aspects of EGFRI treatment. An overview of the EGF signaling pathway is provided, and dermatologic toxicities associated with EGFRI treatment are described. A review of several studies evaluating reactive skin treatment regimens also are discussed. Nurses play a critical role in providing patient support. Informing patients about potential EGFRI-related symptoms and dermatologic toxicities will help prepare patients for their course of treatment. In addition, nurses should provide patients with a variety of coping strategies to help manage dermatologic toxicities that will assist in enhancing patients' adherence to EGFRI treatment.",
author = "Jean Boucher and Linnea Olson and Bilal Piperdi",
year = "2011",
month = "10",
doi = "10.1188/11.CJON.501-508",
language = "English (US)",
volume = "15",
pages = "501--508",
journal = "Clinical Journal of Oncology Nursing",
issn = "1092-1095",
publisher = "Oncology Nursing Society",
number = "5",

}

TY - JOUR

T1 - Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors

AU - Boucher, Jean

AU - Olson, Linnea

AU - Piperdi, Bilal

PY - 2011/10

Y1 - 2011/10

N2 - Epidermal growth factor receptor inhibitors (EGFRIs) are a treatment option for patients diagnosed with advanced-stage gastrointestinal, lung, and head and neck cancers. The most prevalent complications associated with EGFRIs are dermatologic toxicities, which may result in either disruption or discontinuation of treatment and adversely affect patients' quality of life. Nurses play a vital role in educating patients about EGFRI-related dermatologic toxicities; therefore, nurses must continue to educate themselves on the various aspects of EGFRI treatment. An overview of the EGF signaling pathway is provided, and dermatologic toxicities associated with EGFRI treatment are described. A review of several studies evaluating reactive skin treatment regimens also are discussed. Nurses play a critical role in providing patient support. Informing patients about potential EGFRI-related symptoms and dermatologic toxicities will help prepare patients for their course of treatment. In addition, nurses should provide patients with a variety of coping strategies to help manage dermatologic toxicities that will assist in enhancing patients' adherence to EGFRI treatment.

AB - Epidermal growth factor receptor inhibitors (EGFRIs) are a treatment option for patients diagnosed with advanced-stage gastrointestinal, lung, and head and neck cancers. The most prevalent complications associated with EGFRIs are dermatologic toxicities, which may result in either disruption or discontinuation of treatment and adversely affect patients' quality of life. Nurses play a vital role in educating patients about EGFRI-related dermatologic toxicities; therefore, nurses must continue to educate themselves on the various aspects of EGFRI treatment. An overview of the EGF signaling pathway is provided, and dermatologic toxicities associated with EGFRI treatment are described. A review of several studies evaluating reactive skin treatment regimens also are discussed. Nurses play a critical role in providing patient support. Informing patients about potential EGFRI-related symptoms and dermatologic toxicities will help prepare patients for their course of treatment. In addition, nurses should provide patients with a variety of coping strategies to help manage dermatologic toxicities that will assist in enhancing patients' adherence to EGFRI treatment.

UR - http://www.scopus.com/inward/record.url?scp=80053276024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053276024&partnerID=8YFLogxK

U2 - 10.1188/11.CJON.501-508

DO - 10.1188/11.CJON.501-508

M3 - Article

C2 - 21951736

AN - SCOPUS:80053276024

VL - 15

SP - 501

EP - 508

JO - Clinical Journal of Oncology Nursing

JF - Clinical Journal of Oncology Nursing

SN - 1092-1095

IS - 5

ER -